KDventures January-September net loss more than triples year on year to SEK 513.3 million

• KDventures’ third-quarter net loss narrowed 58% year-on-year to SEK 28.2 million.
• Net asset value fell 40% year-on-year to SEK 647.4 million at September-end 2026.
• A fourth-quarter write-down of SEK 226.4 million will eliminate Umecrine Cognition’s carrying value following golexanolone’s failure to meet its primary endpoint.
• Modus Therapeutics temporarily paused sevuparin enrollment following a serious adverse event, shifting its expected proof-of-concept readout to the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.